ArticleClinical journal of gastroenterology2017
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma.
Article in Clinical journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Metastatic pancreatic acinar cell carcinoma withJournal of gastrointestinal oncology · 2025Article
- A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.Clinical journal of gastroenterology · 2024Article
- Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma.Clinical journal of gastroenterology · 2024Article
- Successful curative treatment for a ruptured pancreatic acinar cell carcinoma by radical resection following modified FOLFIRINOX: a case report and literature review.International cancer conference journal · 2024Article
- Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.Japanese journal of clinical oncology · 2024Review
- Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma.Frontiers in oncology · 2024Article
- A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.Current oncology (Toronto, Ont.) · 2023Review
- A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX.Surgical case reports · 2023Article
- Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?Journal of cancer metastasis and treatment · 2023Article
- Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.Cancer reports (Hoboken, N.J.) · 2022Article
- Acinar Cell Carcinoma with Morphological Change in One Month.Internal medicine (Tokyo, Japan) · 2021Article
- Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.OncoTargets and therapy · 2019Article
- Pancreatic acinar cell carcinoma-case report and literature review.BMC cancer · 2018Review
- Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.World journal of surgical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal ultrasonography revealed a pancreatic mass in a 67-year-old man with diabetes mellitus. Endoscopic ultrasound-guided fine needle aspiration led to the histological diagnosis of acinar cell carcinoma. The clinical stage was determined to be IVb based on findings of multiple metastatic lesions in the liver and lymph nodes, as well as splenic vein infiltration. Because the patient was not a surgical candidate, he underwent chemotherapy with modified FOLFIRINOX. In the absence of any severe adverse events, 12 courses of chemotherapy were delivered, resulting in marked shrinkage of both the primary and metastatic lesions. The outcome was judged to be a partial response, which was maintained even 9 months from the introduction of the chemotherapy. The results of this case suggest that modified FOLFIRINOX is safe and effective in the treatment of pancreatic acinar cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.